Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
SINT Catalyst Timeline
Dated clinical, regulatory and corporate events for SiNtx Technologies, Inc.
Past FDA Catalysts and PDUFA Decisions
How SINT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
SiNtx Technologies, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SINT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Elmore Robert RyanOfficer (President) | Grant/Award | 4,910 4,910 held | $2.89 | 04/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SINT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SINT for Q3 2026. | ||||
Ownership Trends
SINT Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SINT ranks across every disease it competes in
SINT News
SINTX Strengthens Patent Portfolio to Support International Growth Across Healthcare Markets
SINTX Technologies announced the issuance of two patents and three allowed applications, enhancing its intellectual property portfolio. These developments support the company's plans for international commercialization of its silicon nitride technologies across orthopedic devices, biomaterials, and medical textiles. The CEO emphasized the importance of robust IP protection for future growth.
Read more →SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization
SINTX Technologies has completed its advanced 3D printing facility and is advancing its SiN/PEEK technology for personalized orthopedic implants. The company aims for initial product availability in 2027 and is pursuing FDA 510(k) clearance. SINTX plans to expand into craniomaxillofacial and spinal applications later in 2027, contingent on regulatory approvals.
Read more →SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization
SINTX Technologies reported a significant revenue increase of over tenfold year over year for Q3 2026, alongside a 51% reduction in operating losses. The company is advancing its commercialization efforts, particularly with the launch of its SiNAPTIC® Foot & Ankle Osteotomy Wedge System. SINTX is optimistic about future growth opportunities in healthcare and other applications.
Read more →SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast
SINTX Technologies announced it will release its third quarter 2026 financial results on November 5, 2026. A conference call and webcast will follow at 4:30 p.m. ET, featuring CEO Eric Olson and CFO Kevin Trask. Interested parties can access the webcast through the company's investor relations website.
Read more →SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
SINTX Technologies reported preliminary Q3 revenue of $2.2 million, exceeding its guidance of $0.9 million to $1.1 million. This represents a 380% increase from Q2, primarily driven by industrial sales to Fortune 500 customers. The company anticipates narrower losses and continues to develop its silicon nitride technology platform.
Read more →SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts
SINTX Technologies announced a Masterclass on silicon nitride in orthopedics, featuring expert discussions on its advantages over traditional materials. The event aims to educate orthopedic professionals about the material's unique properties and potential applications. SINTX is transitioning towards a medical device focus, expanding its use of silicon nitride in various orthopedic markets.
Read more →SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SINTX Technologies will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company's executives will discuss advancements in the FDA-cleared SINAPTIC® Foot & Ankle Implant System and its proprietary silicon nitride technology. They aim to enhance commercial opportunities and support shareholder value.
Read more →SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement
SINTX Technologies has announced that it has regained compliance with Nasdaq's stockholders' equity requirement. This notification from the Listing Qualifications Staff is a positive development for the company, which specializes in advanced silicon nitride materials and medical technologies. The compliance may improve investor confidence in SINTX's financial standing.
Read more →SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives
SINTX Technologies provided a mid-year business update, emphasizing its successful commercial execution and expansion of its biomaterial platform. The company outlined various strategic growth initiatives aimed at enhancing its market position. This update reflects SINTX's commitment to advancing its technology in medical and industrial applications.
Read more →SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast
SINTX Technologies announced it will release its second quarter 2026 financial results on August 11, 2026. A conference call and webcast will follow at 4:30 p.m. ET, featuring CEO Eric Olson and CFO Kevin Trask. Interested parties can access the webcast via the company's investor relations website.
Read more →SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program
SINTX Technologies hired Southern Metrics Consulting to manage its new Strategic Opportunity Management Program. Chris Lyons leads the firm and serves on the SINTX board. The company aims to evaluate partnerships and acquisitions to support growth. This move signals SINTX's shift toward a commercial-stage medical technology business.
Read more →SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders
SINTX Technologies announced it secured over $3.2 million in purchase orders for advanced ceramic components from multiple customers. The company expects production to start in the second half of 2026 and continue into 2027. This reflects growing customer interest in SINTX's manufacturing capabilities and technical expertise.
Read more →MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and $6 Price Target
MAXIM Group has resumed coverage on SINTX Technologies, assigning a Buy rating and a price target of $6. The report emphasizes SINTX's FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System and its expanding commercialization strategy. Analysts also noted the company's proprietary manufacturing capabilities and 3D-printing initiatives as key growth drivers.
Read more →SiNtx Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market
SINTX Technologies, Inc. has announced a capital raise of approximately $5.0 million, including a $4.5 million private placement priced at-the-market. The offering involves issuing 1,882,845 shares of common stock along with corresponding warrants to accredited investors. The funds are earmarked for general corporate purposes, especially in advancing the company's silicon nitride technology. The financing reflects strong investor support and is expected to enhance SINTX's strategic capabilities in the medical application sector.
Read more →SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride-PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants
SINTX Technologies has signed a significant supply agreement with EVONIK to manufacture its proprietary silicon nitride-PEEK (SiN/PEEK) compound. This collaboration allows for the immediate production of AI-assisted, 3D-printed, patient-specific implants at SINTX's facility in the U.S. The agreement will enable SINTX to respond to physician requests for humanitarian-use vertebral body replacement implants, addressing critical needs in trauma and oncology. The SiN/PEEK compound is anticipated to offer advantages over standard PEEK materials.
Read more →SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies
SINTX Technologies, Inc. reported a pivotal business update for the third quarter of 2025, highlighting key achievements including FDA clearance for its SINAPTIC Foot & Ankle Osteotomy Wedge System and its first commercial revenue from OsseoSculpt. The company's financial highlights show a reduction in operating expenses and improved liquidity through a recent financing activity. However, revenue has decreased compared to the previous year, raising concerns despite strong operational efficiencies and portfolio expansions. Looking ahead, SINTX plans to focus on launching the SINAPTIC wedge system and expanding clinical engagement.
Read more →SiNtx Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market
SINTX Technologies has submitted a 510(k) premarket notification to the FDA for its silicon nitride osteotomy wedges, marking its entry into the reconstructive foot and ankle market. The company emphasizes the advanced biomaterial's benefits, including improved bone integration and reduced infection rates, as well as proprietary implant designs aimed at enhancing surgical efficiency. This development is projected to drive significant revenue growth, with expectations for strong early adoption by healthcare providers. However, the company acknowledges that the approval process and commercialization may encounter uncertainties.
Read more →SiNtx Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities
SINTX Technologies announced the acquisition of SiNAPTIC Holdings' surgical business assets, enabling entry into the $1.3 billion foot and ankle fusion market. This acquisition includes all intellectual property and product designs related to six differentiated implant systems, aiming to accelerate commercial growth. The deal, viewed as transformative, will likely shift SINTX's focus from R&D towards revenue generation, assisted by SiNAPTIC's experienced team. However, achieving success will depend on effective commercialization and navigating regulatory hurdles.
Read more →SiNtx Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market
SINTX Technologies has announced the issuance of an international patent for silicon nitride applications in agriculture, specifically for antimicrobial treatment and plant protection. The company is expanding into the agribiotech market with the formation of a subsidiary, SINTX Agribiotech, which will focus on developing sustainable agricultural technologies. Expected growth in the global antimicrobial fertilizer market highlights the potential for silicon nitride, which has shown promising results in preventing crop diseases. Nevertheless, the company acknowledges that commercialization challenges could impact future success.
Read more →SiNtx Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization Lake City, UT - May 15, 2025 - SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical
SINTX Technologies, Inc. has announced a business update detailing its strategic shift toward medical device commercialization, focusing on silicon nitride applications. The company reported improved financials, including a cash increase and reduced operating costs. Highlighting advanced research programs and partnerships with medical OEMs, SINTX aims to meet critical healthcare needs. However, the transition carries risks related to product commercialization and market acceptance.
Read more →